Thermo Fisher Scientific (NYSE:TMO) Shares Gap Up to $548.38

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $548.38, but opened at $567.51. Thermo Fisher Scientific shares last traded at $568.03, with a volume of 518,787 shares traded.

Analyst Ratings Changes

A number of brokerages have recently issued reports on TMO. Barclays downgraded shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $475.00 to $555.00 in a research report on Wednesday, January 24th. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Evercore ISI boosted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Royal Bank of Canada lifted their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Finally, Raymond James lifted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Price Performance

The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The firm has a market capitalization of $218.58 billion, a P/E ratio of 35.49, a P/E/G ratio of 2.30 and a beta of 0.80. The stock’s 50 day simple moving average is $571.30 and its 200 day simple moving average is $528.18.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the firm earned $5.40 earnings per share. The company’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock worth $28,513,384 over the last 90 days. 0.32% of the stock is currently owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently modified their holdings of TMO. Northwest Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. True Wealth Design LLC lifted its stake in shares of Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after buying an additional 51 shares in the last quarter. Pineridge Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $39,000. Cape Investment Advisory Inc. lifted its stake in shares of Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after buying an additional 26 shares in the last quarter. Finally, Raleigh Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.